

BIOLASE, INC
Form 8-K
January 09, 2017

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 9, 2017

BIOLASE, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State of

Incorporation)

001-36385
(Commission

File Number)
4 Cromwell

87-0442441
(IRS Employer

Identification Number)

Edgar Filing: BIOLASE, INC - Form 8-K

Irvine, California 92618

(Address of principal executive offices) (Zip Code)

(949) 361-1200

(Registrant's telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On January 9, 2017, Harold C. Flynn, Jr., President and Chief Executive Officer of Biolase, Inc. (the Company), will participate in investor presentations at the 35th Annual JP Morgan Healthcare Conference in San Francisco, California that include a written communication comprised of slides. The slides from the presentations are attached hereto as Exhibit 99.1, and are hereby incorporated by reference.

A copy of the slides will be available for viewing and download at <http://www.biolase.com/investors> for a period of 30 days.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 Presentation material with investors from the 35th Annual JP Morgan Healthcare Conference, dated January 9, 2017.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOLASE, INC.

Date: January 9, 2017

By: */s/ David C. Dreyer*
David C. Dreyer
SVP and Chief Financial Officer

Exhibit Index

Exhibit No.	Description
99.1	Presentation material with investors from the 35th Annual JP Morgan Healthcare Conference, dated January 9, 2017.